The short answer
It is not established that berberine changes linagliptin absorption or clinical effectiveness. Have the pharmacist review the product; enzyme findings from other test drugs do not provide an exact dose adjustment.
What this answer covers
Oral berberine supplement; botanical source and dose must be specified.
- Supplement or preparation
- Berberine
- Medication ingredient
- linagliptin
What was actually measured
Repeated berberine increased exposure to midazolam, a test drug for CYP3A4 activity, in healthy volunteers. Linagliptin concentrations and absorption were not measured.
How the medicine label applies
Linagliptin undergoes limited metabolism. Its label’s warning about strong enzyme or transporter inducers cannot be applied to an inhibition finding with berberine. A glucose effect from berberine is also different from changing linagliptin absorption.
Bring the complete product label
Record the species or ingredient, extract strength, daily amount and start date. Report glucose changes so the clinician can assess supplement effects alongside meals and other medicines.
Keep the prescribed medicine plan
Continue the prescribed linagliptin dose and review the complete medicine and supplement list with the pharmacist. A new supplement is not a reason to adjust this medicine yourself or invent a separation interval.
Evidence and practical considerations
Absorption & effectiveness
Original absorption/effectiveness claim remains insufficient: human probe findings require an untested medication-specific bridge.
- Exact scope
- Oral berberine supplement; botanical source and dose must be specified. with Exact linagliptin single-ingredient oral tablets. Exact RxNorm IN1100699 linagliptin; single-ingredient oral tablets. Combination medicines are not assumed equivalent.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No direct exact-pair human pharmacokinetic or clinical-effect study identified; no safe dose or protective spacing established.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline glucose and nutrient status.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed linagliptin.
Glucose-dependent DPP4 action; increased hypoglycemia with insulin/secretagogues. Strong P-gp/CYP3A4 inducers reduce exposure; CYP3A4 inhibition does not automatically imply a clinically relevant change.
How this applies: Exact RxNorm IN1100699 linagliptin; single-ingredient oral tablets. Combination medicines are not assumed equivalent.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Healthy male volunteers in crossover study.
Midazolam exposure increased about 40%; CYP2D6 and CYP2C9 probe measures changed. Other tested probe pharmacokinetics did not significantly change.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Neither linagliptin nor saxagliptin was studied. This does not establish a strong CYP3A4-inhibitor classification, intestinal absorption change or clinical toxicity.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Adults with newly diagnosed or poorly controlled type 2 diabetes in two pilot cohorts.
Glycemic measures improved; transient gastrointestinal adverse effects were reported.
How this applies: Only the named original drug, preparation, route and endpoint apply; no untested exact medication transfer.
Small pilot studies; no linagliptin co-use, no exact-pair hypoglycemia estimate or assumed equivalence to every botanical source of berberine.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: 908b2ff8069ee600
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.